TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Hepatitis C Therapy and Bone Health

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HCV antibody and HCV RNA positive~2. HCV Genotype 1a, 1b, or 4~3. Liver staging assessment:~   a. Cirrhosis will be defined by any of the following: i. A liver biopsy prior to day 1 of this study showing cirrhosis (F4) ii. Fibroscan within 12 calendar months of day 1 of this study showing cirrhosis with result \> 12.5 kPa iii. FibroSURE performed during screening with a score \> 0.75 and APRI \> 2 b. Absence of cirrhosis will be defined by any of the following: i. Liver biopsy performed within 24 months of day 1 of this study showing absence of cirrhosis ii. Fibroscan performed within 12 months of day 1 of this study with a result of ≤ 12.5 kPa iii. FibroSURE score ≤ 0.48 and APRI ≤ 1 during screening~4. If HIV co-infected, HAART regimen will consist of two NRTIs (abacavir, tenofovir disoproxil fumarate or tenofovir alafenamide, each in combination with lamivudine or emtricitabine) with one of the following 3rd agents:~   1. raltegravir~  2. dolutegravir~  3. rilpivirine HIV co-infected patients must be on their stable HAART regimen for at least 6 months, with HIV viral load \< 50 c/mL at screening~Exclusion Criteria:~1. Hepatitis B surface antigen positivity~2. Decompensated cirrhosis (Child Pugh B or C)~3. Any prior hepatitis C treatment~4. Pregnant or nursing~5. Treatment with any medication specifically contraindicated with EBR/GZR or not recommended for concomitant use as per the prescribing label (Table 2)~6. Age less than 18~7. Prisoners or subjects otherwise involuntarily incarcerated~8. Absence of signed informed consent by patient or appropriate surrogate~9. Known hypersensitivity to elbasvir or grazoprevir~10. For patients with genotype 1a, one more of the following mutations on baseline NS5A genotype: M28, Q30, L31, or Y93

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- EBR/GZR (Zepatier) - HCV/HIV co-infected (Type: EXPERIMENTAL): Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
- EBR/GZR (Zepatier) - HCV monoinfected (Type: EXPERIMENTAL): Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ozone Therapy for Lumbar Herniated Disc

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of herniated disc by surgeons from participating hospitals~* Sciatic pain of 5 or more on Visual Analogue Scale~* Pain radiated to appropriate area according to herniated disc~* On waiting list for disc surgery at one of participating hospitals~Exclusion Criteria:~* Inability to fill out questionnaires (VAS, Roland Morris, SF12)~* Calcified or migrated herniated disc~* Herniated disc with indications for laminectomy or arthrodesis~* Clinically relevant partial paralysis~* Simultaneous cervical and dorsal symptomatic herniated discs~* Previous lumbar spine surgery~* Presence of other spinal pathology~* Significant glucose-6-phosphate-dehydrogenase deficit~* Allergy to ozone~* Treatment with oral anticoagulants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Discectomy/micro discectomy
- 2 (Type: ACTIVE_COMPARATOR): Intradiscal ozone infiltration
- 3 (Type: ACTIVE_COMPARATOR): Intradiscal oxygen infiltration (control arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Doppler Ultrasound in Severe Peptic Ulcer Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clean base ulcer with severe upper GIB (defined as melaena, hematochezia, hematemesis, and/or gross blood in NG lavage), and any one of the following:~  1. SBP ≤ 90mmHg; P of ≥110 bpm; or orthostatic changes with SBP drops 20mmHg or P increases 20 bpm; or,~ 2. Transfusion of 2 or more units of packed red blood cells within 12 hrs of admission; or,~ 3. A documented HCT drop of at lest 6% from baseline.~* Endoscopically confirmed bleeding from GU, DU, pyloric ulcer, or anastomotic ulcer~* Pt can either have primary or secondary acute UGI haemorrhage~Exclusion Criteria:~* Bleeding site from lesion other than GU, DU, pyloric or anastomotic ulcer~* there is more than one type of significant bleeding lesion~* Documented hx of cirrhosis / portal HT~* ESRF requiring any form of dialysis~* Expected or persistent (\>24hrs) coagulopathy with INR\> 1.5~* Platelet count is under 50000/mm3~* Aspirin User / Plavix \[Clopidogrel\] User~* If the ulcer is neoplastic~* Cannot obtained consent~* Age \< 18 or is pregnant~* Severe comorbid of which life expectancy \<30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doppler ultrasound (Type: ACTIVE_COMPARATOR): None
- No Doppler ultrasound (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female aged between 18 and 70~* capable of reading and understanding the information leaflet given to him/her~* signed an inform consent form~* presenting with idiopathic Parkinson's disease with a Hoehn and Yahr score of ≤ 3~* has never been given anti-Parkinson medication, or has been treated with L-Dopa, on condition that the total duration of treatment was less than twelve weeks at a dosage of under 200 mg, or has been treated with a dopamine agonist other than Pramipexole, on condition that:~  * either the patient is still in the dose-titration phase at the time of inclusion~ * or that the treatment was administered for less than six weeks and was completed two weeks before inclusion~Exclusion Criteria:~* women who are pregnant, breastfeeding, or planning a pregnancy in the months after joining the study~* women of reproductive age who have not undergone surgical sterilisation or who are not using a reliable method of contraception before joining the study and during the study~* patient presenting with hepatic insufficiency~* patient presenting with a concommitant illness which is considered significant by the investigator, after examination of the history, the patient's clinical condition, or on the basis on any additional examinations performed~* patient presenting with a skin lesion considered to be suspect by the investigator and which has not been evaluated by a dermatologist~* patient presenting with a contraindication to treatment with Rasagiline or Pramipexole (please see the SPC for the respective products)~* patient treated with fuoxetine during the five weeks preceding inclusion~* patient treated with fluvoxamine, pethidine, selegiline or any other MAOI during the two weeks preceding inclusion~* patient who has had deep brain stimulation treatment~* patient who might receive dextromethorphan or a sympathomimetic during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rasagiline (Type: EXPERIMENTAL): None
- Pramipexole (Type: ACTIVE_COMPARATOR): pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Kidney Disease stage 1-5~* Hyperuricemic (UA \>= 5.5 mg/dL)~Exclusion Criteria:~* Contraindication to Allopurinol~* Elevated baseline liver function tests~* Receiving acute or chronic dialysis~* Primary metabolic disorder~* Sickle cell disease~* Autosomal Dominant Polycystic Kidney Disease~* Cystinosis~* Bartter or Gitelman Disease~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Allopurinol (Type: ACTIVE_COMPARATOR): Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
- Standard of Care Control (Type: NO_INTERVENTION): The treatment arm will be compared to a standard of care arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who satisfy more than 4 criteria for diagnosis of systemic lupus erythematosus (ARA criteria, 1982)~* Patients who fall under WHO class III-IV lupus nephritis on renal biopsy~* Patients with refractory lupus nephritis~* Proteinuria ≥ 0.5 g/day~* Patients who took steroid ≥ 20 mg/day over one month prior to the study~* Patients who failed a first-line therapy (non-responders to steroid monotherapy)~Exclusion Criteria:~* Patients who are allergic or resistant to macrolide antibiotics or tacrolimus~* Patients who received tacrolimus in the past (excluding drugs for external use)~* Patients who used other immunosuppressants within 4 weeks before initiation of the study~* Patients who have been receiving systematic chemotherapy since before enrollment (local chemotherapy is allowed.)~* Patients with malignant tumor which developed within the recent 5 years or history of malignant tumor~* Patients who have severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorders which may influence absorption of tacrolimus~* Patients with S-Cr ≥ 200 µ㏖/L or ≥ 2.3 mg/dL~* Patients with liver function levels of more than twice the upper limit of normal or acute active hepatitis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus group (Type: EXPERIMENTAL): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clonidine for Neonatal Abstinence Syndrome Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 0 to 15 days of age~* Prenatal exposure to opioids with development of moderate to severe NAS (2 consecutive abstinence scores of ≥ 8)~* Medically stable~Exclusion Criteria:~* Gestational age \< 35 weeks~* Intrauterine growth retardation (birth weight below the 5th percentile)~* Congenital heart disease~* Congenital anomalies~* Medically unstable~Exposure to Benzodiazepines prenatally~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Days
- Healthy Volunteers: f

Study Arms:
- NMS/Clonidine (Type: EXPERIMENTAL): None
- NMS/Phenobarbital (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Bypass or Thurpass for Superficial Femoral Artery Occlusion? Scandinavian Thurpass Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Superficial femoral artery occlusion from 5 to 25 cm in length above the knee joint.~2. Patient must be equally eligible for both procedures.~3. Patient must present intermittent claudication with resistance to medical therapy and exercise or critical ischaemia.~4. Normal adjacent vessel diameter must be between 4.8 and 6.5 mm.~5. At least one patent distal run-off vessel and at least 1 cm of healthy superficial femoral artery below and above the lesion to allow proper placement of the endoprosthesis.~6. Patient must be 18 years or older.~7. Women of childbearing age must have negative pregnancy test prior to inclusion.~Exclusion Criteria:~1. Known allergy or contraindications to aspirin, clopidogrel, dipyridamole or anticoagulants.~2. Bleeding diatheses~3. Presence of one or several previously placed endoprosthesis or grafts in the superficial femoral artery segment.~4. Planned other endovascular therapy of the same segment.~5. Other than 6-7 mm diameter endoprosthesis or 6 mm PTFE-prosthesis is needed.~6. Presence of evolving malignant cancer or any other illness posing an immediate threat to life.~7. Life-expectancy less than 2 years due to co-morbidity or other situation that would make the patient unlikely candidate for follow-up visits.~8. Participation in another vascular clinical study less than 30 days prior to inclusion.~9. Patients unable to fill out the prescribed quality of life questionnaires themselves or unable to understand the full meaning of the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thrupass (Type: OTHER): Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
- Bypass (Type: OTHER): Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least three years from completion of treatment for Hodgkin's Disease~* Age 18- 35~* Ability to complete self report questionnaires in either English or Spanish~* Willingness of patient, or parent/guardian if patient less than 18 years of age to sign consent to participate in study~* Willingness of patient to sign assent if greater than 7 years of age and less than 18 years~Exclusion Criteria:~* Pregnant or breast feeding~* Tanner Stage 1~* Currently taking cyclosporine, niacin, antiretrovirals, macrolide antibiotic, azole antifungal~* Liver enzymes greater than 1.5 times the upper level of normal~* Creatine Kinase greater than 2 times the upper level of normal~* Use of estrogen containing contraceptive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- A Intervention Arm (Type: EXPERIMENTAL): Escalating dose of simvastatin in subjects who are survivors of Hodgkin Lymphoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The SNORES Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Females 18 - 50 years old.~* Receiving care from an Obstetrician / gynecologist or a Reproductive endocrinology infertility specialist~* Polycystic ovarian syndrome defined by the modified Rotterdam criteria~* Able to speak and understand as well as give informed consent in English~Exclusion Criteria~* Late onset congenital adrenal hyperplasia~* Cushings disease~* Androgen-secreting tumors~* Previous diagnosis of obstructive sleep apnea~* Current use of over the counter or prescribed sleep medications.~  * Examples of medications that exclude a patient from this study include but are not limited to Unisom, Ambien or Lunesta.~ * Patients who are taking non-prescribed herbal medications for sleep will not be excluded from the study. Examples of these include but are not limited to melatonin, chamomile, or valerian.~* Untreated thyroid disease~* Prolactin excess~* Patients with the following medical conditions will be excluded from the study as portable sleep apnea monitors are not indicated in patients with severe pulmonary disease, neuromuscular disease, or congestive heart failure.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Usual care (Type: NO_INTERVENTION): None
- Screen for Sleep Apnea (Type: EXPERIMENTAL): Screen for sleep apnea, treat with continuous positive airway pressure (CPAP) if diagnosed with sleep apnea

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Unexplained Recurrent Abortion by Enoxaparine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women between 18 and 45 years~* 2 or more consecutive spontaneous abortions before the 15th week of pregnancy~* Unexplained abortions~* No maternal or paternal characterized chromosomal aberration~* No Anti-phospholipid Syndrome~* No anatomical abnormality possibly responsible for abortion~* No Factor V Leiden~* No Prothrombin G20210A mutation~* No protein S deficiency~* No protein C deficiency~* No Anti thrombin 3 deficiency~* Proved pregnancy~Exclusion Criteria:~* Contraindications of enoxaparine 4000 U per day~* Women with risk of venous thromboembolism during pregnancy~* No regular anticoagulation or antiplatelet treatment~* Blood Hemoglobin level below 10g/dl~* Blood platelet level below 150 000/mm3~* Creatinine clearance below 30ml/mn~* Anomaly of the coagulation tests~* No informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with brain tumors will be enrolled. These subjects may be newly diagnosed, undergoing treatment or undergoing follow-up. If a subject has undergone surgery or treatment they should have what appears to be residual tumor.~Exclusion Criteria:~* Renal failure (GFR \<45). Subjects will be screened utilizing UNMC gadolinium contrast guidelines.~* Allergic reactions to MRI contrast agents.~* Subjects who do not fit the criteria for the population we are evaluating.~* Subjects should not participate in this study if they have any of the following conditions:~  * Anxiety attacks~ * Panic disorder~ * Claustrophobia~ * Pregnant, or trying to become pregnant~ * Breast feeding~* Subjects should not participate in this study if they have certain kinds of metal in their body, for example: a heart pacemaker, defibrillator, neurostimulator, a metal plate, certain otologic implants, certain types of heart valves, metal slivers in eye, brain aneurysm clips or metal slivers and bullet fragments in or near certain structures in their body. Our standard MRI safety screening will be performed on all subjects.~* If a subject has metal in their body that requires an additional x-ray beyond what is needed for the clinical MRI examination to safely perform the research MRI examination that subject would be excluded.Subjects not being able to return for a follow-up examination

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy